Three Current Drivers for the Stock Price!
The collaboration with Ipsen is paying off for Genfit with milestone payments. In the long term, Genfit could become a takeover candidate!
Reading Time: 1 minute
Genfit S.A. (i.) is a biotechnology company specializing in rare and life-threatening liver diseases. Currently, the stock is back in favor with investors for three reasons. 1. On May 21, it was announced that Iqirvo from Ipsen has received pricing and reimbursement approval in Italy for the treatment of primary biliary cholangitis (PBC). This milestone entitles Genfit to a milestone payment of €26.5 million from Ipsen. With these fresh liquid funds, the company can further advance its product pipeline in the area of acute-on chronic liver failure...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
